The role of BCL-2 family proteins in regulating apoptosis and cancer therapy
S Qian, Z Wei, W Yang, J Huang, Y Yang… - Frontiers in …, 2022 - frontiersin.org
Apoptosis, as a very important biological process, is a response to developmental cues or
cellular stress. Impaired apoptosis plays a central role in the development of cancer and …
cellular stress. Impaired apoptosis plays a central role in the development of cancer and …
PROTACs: great opportunities for academia and industry
X Sun, H Gao, Y Yang, M He, Y Wu, Y Song… - Signal transduction and …, 2019 - nature.com
Although many kinds of therapies are applied in the clinic, drug-resistance is a major and
unavoidable problem. Another disturbing statistic is the limited number of drug targets, which …
unavoidable problem. Another disturbing statistic is the limited number of drug targets, which …
Hepatocellular carcinoma immunotherapy
RC Sperandio, RC Pestana… - Annual review of …, 2022 - annualreviews.org
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third
leading cause of cancer-related death worldwide. Single-agent anti-PD-1 immune …
leading cause of cancer-related death worldwide. Single-agent anti-PD-1 immune …
Changes in glutathione content in liver diseases: an update
Glutathione (GSH), a tripeptide particularly concentrated in the liver, is the most important
thiol reducing agent involved in the modulation of redox processes. It has also been …
thiol reducing agent involved in the modulation of redox processes. It has also been …
MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway
G Lou, L Chen, C Xia, W Wang, J Qi, A Li… - Journal of Experimental …, 2020 - Springer
Abstract Background MiR-199a-3p (miR-199a) can enhance the chemosensitivity of
hepatocellular carcinoma (HCC). Because of the easy degradation of miRNA by direct …
hepatocellular carcinoma (HCC). Because of the easy degradation of miRNA by direct …
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
S Zeng, W Huang, X Zheng, Z Zhang, J Wang… - European journal of …, 2021 - Elsevier
Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3
ligase for target degradation via the ubiquitin-proteasome pathway, is a novel drug …
ligase for target degradation via the ubiquitin-proteasome pathway, is a novel drug …
[HTML][HTML] Immune-based therapies for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death.
The immune-rich contexture of the HCC microenvironment makes this tumour an appealing …
The immune-rich contexture of the HCC microenvironment makes this tumour an appealing …
Exosomes as drug delivery systems: A brief overview and progress update
Exosomes are intracellular membrane-based vesicles with diverse compositions that are
involved in biological and pathological processes. Since the discovery of exosomes, they …
involved in biological and pathological processes. Since the discovery of exosomes, they …
A Sodium Alginate‐Based Multifunctional Nanoplatform for Synergistic Chemo‐Immunotherapy of Hepatocellular Carcinoma
C Huang, T Xie, Y Liu, S Yan, F OuYang… - Advanced …, 2023 - Wiley Online Library
Efficient hepatocellular carcinoma (HCC) treatment remains a significant challenge due to
the inherent limitations of traditional strategies. The exploration of polysaccharides' natural …
the inherent limitations of traditional strategies. The exploration of polysaccharides' natural …
Sorafenib resistance in hepatocellular carcinoma: the relevance of genetic heterogeneity
Despite advances in biomedicine, the incidence and the mortality of hepatocellular
carcinoma (HCC) remain high. The majority of HCC cases are diagnosed in later stages …
carcinoma (HCC) remain high. The majority of HCC cases are diagnosed in later stages …